Introduction: Hepatitis C virus (HCV) infection is a global public health burden, total global HCV 
prevalence is estimated at 2.5% (177 million of HCV infected adults), Considerable differences are 
present among different populations. For example, the HCV prevalence in Egypt is 10-15%. Aim of 
the study: The aim of this study is to determine the effect of treatment with DAAs on serum lipids 
(total cholesterol, low and high density cholesterol, triglycerides, ox LDL) and Insulin Resistance 
(HOMA_IR) in chronic HCV patients. Patients and Methods: Study design: Our Prospective study 
aimed to determine the effect of treatment with Direct Acting Antivirals (DAAs) on lipid and glucose 
metabolism in chronic hepatitis C patients. Results: Eighty six chronic hepatitis c patients were 
included in this study, the patients were consecutively from admitted and/or attendant of out patient's 
clinic of Tropical Medicine Department, Minia University Hospitals. The main results of the study 
were summarized in the following tables and figures. Conclusion: The DAAs therapy is highly 
effective in treatment of chronic hepatitis c patients especially (SOF/DAC) regimen, reaching about 
100% SVR.